Lantheus (LNTH) Gains 33.3% YTD: What's Driving the Stock?

Lantheus' leadership in the radiopharmaceuticals market, with PYLARIFY dominating PSMA PET imaging for prostate cancer, looks promising. The company is expanding its pipeline with promising assets like PNT2002, PNT2003, and MK-6240, along with strategic collaborations to enhance its portfolio, including in oncology. Revenues in the Radiopharmaceutical Oncology segment were up 32.1% year over year. The segment's performance reflected solid PYLARIFY sales, driven by increasing utilization of PSMA PET with PYL ...